Boost Your Way to the Clinic! (5)

Why our anti-P2X4 antibodies could be your next lead candidate?

At ProteoGenix, we’ve partnered with Cube Biotech to bring a new breakthrough in therapeutic antibody development: TWO recombinant antibodies targeting P2X4.

Fully Human: No Need For Further Humanization
stable pool
High Binding Affinity Confirmed To Native Human P2X4
antigen
High Production Yield & High Purity Validated
developability study
Free Of Intellectual Property
Design sans titre-1

Discover the three breakthrough technologies used to develop anti-P2X4 antibodies

NativeMP™ copolymer platform
NativeMP™ copolymer platform - Native-like nanodiscs Functional integrity Structural integrity

Learn more

Human Phage Display Library
Built from PBMCs of 458 diverse donors of 5 different ethnic groups
Contain 60 billions different antibodies

Learn more

Recombinant Antibody Production
Proprietary Mammalian Expression System XtenCHO

Learn more